News

Atai Life Sciences is making incremental progress towards opening door for a first psychedelic treatment for depression. Read ...
Life Sciences & Beckley Psytech announce positive results from phase 2b study of BPL-003 in patients with treatment-resistant depression: New York Wednesday, July 2, 2025, 10 ...
The transaction will provide Supernus with an innovative marketed product: ZURZUVAE® (zuranolone) capsules CIV, the first and only U.S. Food and Drug Administration (FDA)-approved oral medicine ...
Deep transcranial magnetic stimulation was safe and effective in treating adolescents and young adults with major depressive ...
The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...
The growing global burden of neuropsychiatric disorders is a critical driver for the treatment market. With over 9.1 million annual deaths attributed to neurological diseases and an additional 8 ...
Shares of ATAI Life Sciences (NASDAQ:ATAI) skyrocketed 29% on Tuesday after the biotech company and its partner, Beckley ...
Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the next stage of the biotech’s planned merger with mental health company ...
Shares of atai Life Sciences (NASDAQ:ATAI) traded higher in the premarket on Tuesday after the company and its partner, ...
Compass Pathways has announced that its investigational psilocybin therapy, COMP360, met the primary endpoint in its Phase 3 ...
While ALTO-203 missed its depression-related endpoints, improvements in EEG biomarkers, attention and wakefulness point to ...
Lipocine is expecting to use the data from this trial to support a new drug application submission in mid-2026.